FibroBiologics, Inc. (FBLG)
NASDAQ:FBLG
Want to see FBLG full AI Analyst Report?
FBLG Stock Chart & Stats
$1.53
-$0.09(-3.98%)
At close: 4:00 PM EST
$1.53
-$0.09(-3.98%)
Day’s Range― - ―
52-Week Range$0.95 - $19.78
Previous CloseN/A
Volume56.64K
Average Volume (3M)978.93K
Market Cap
$6.04M
Enterprise Value$3.18M
Total Cash (Recent Filing)$1.48M
Total Debt (Recent Filing)$2.23M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Jul 30, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.22
Shares Outstanding5,208,915
10 Day Avg. Volume1,423,641
30 Day Avg. Volume978,931
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.60
Enterprise Value/Ebitda-0.18
Forecast
1Y Price Target
$8.00Price Target Upside422.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthCapital raised and repayment of outstanding debt reduces near-term financial pressure and helps sustain clinical development without immediate reliance on additional funding.
Clinical ValidationInterim proof-of-concept results in the diabetic foot ulcer trial may validate the fibroblast platform and support higher valuation along with broader clinical development opportunities.
Manufacturing ScalabilityAllogeneic donor fibroblast differentiation enables scalable sourcing and manufacturing of topical spheroid products, which can lower production costs and support larger commercial supply.
Bears Say
Data Sensitivity And Valuation RiskInterim trial data will strongly influence market perception, and unfavorable efficacy or safety signals could materially reduce the company's valuation and investor confidence.
Financing And Dilution RiskExpectation of additional capital raises creates the risk of shareholder dilution and downward pressure on the stock if future financing terms are unfavorable.
Trial Execution And Operational RiskUncertainty about trial start timing, manufacturing completion, and patient enrollment increases the risk of delays to clinical milestones that underpin the stock's outlook.
FibroBiologics, Inc. News
FBLG FAQ
What was FibroBiologics, Inc.’s price range in the past 12 months?
FibroBiologics, Inc. lowest stock price was $0.95 and its highest was $19.78 in the past 12 months.
What is FibroBiologics, Inc.’s market cap?
FibroBiologics, Inc.’s market cap is $6.04M.
When is FibroBiologics, Inc.’s upcoming earnings report date?
FibroBiologics, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 60 days.
How were FibroBiologics, Inc.’s earnings last quarter?
FibroBiologics, Inc. released its earnings results on Apr 30, 2026. The company reported -$1.255 earnings per share for the quarter, beating the consensus estimate of -$1.334 by $0.079.
Is FibroBiologics, Inc. overvalued?
According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued.
Does FibroBiologics, Inc. pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
What is FibroBiologics, Inc.’s EPS estimate?
FibroBiologics, Inc.’s EPS estimate is -0.83.
How many shares outstanding does FibroBiologics, Inc. have?
FibroBiologics, Inc. has 5,208,915 shares outstanding.
What happened to FibroBiologics, Inc.’s price movement after its last earnings report?
FibroBiologics, Inc. reported an EPS of -$1.255 in its last earnings report, beating expectations of -$1.334. Following the earnings report the stock price went up 10.606%.
Which hedge fund is a major shareholder of FibroBiologics, Inc.?
Currently, no hedge funds are holding shares in FBLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
FibroBiologics, Inc.
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
FBLG Stock 12 Month Forecast
Average Price Target
$8.00
▲(422.88% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Curis
―
Synlogic
―
Lexaria Bioscience
―
Processa Pharmaceuticals
―